Somite AI has secured $60,000,000 in a recent funding round. This substantial capital infusion will support the company's mission to advance novel cell therapies through its innovative application of artificial intelligence. This latest investment follows the company's prior pre-seed funding of over $11 million, indicating continued investor confidence in its technological approach and strategic vision.
Based in Boston and having launched operations in January 2024, Somite AI specializes in developing AI foundation models specifically for human stem cells. The company employs a full-stack approach, generating data at significantly reduced costs, training large-scale predictive models, and utilizing these models to discover, refine, and optimize high-impact applications within the cell therapy field. This integrated methodology aims to address key challenges in developing scalable cell therapies.
The newly raised capital is earmarked to accelerate Somite AI's research and development initiatives, expand its operational capabilities, and strategically grow its team of AI and cell biology experts. This funding round is critical for scaling the company's data generation processes and further developing its foundational AI models, which are central to its strategy of transforming the cell therapy landscape.
Somite AI's founding team brings together a unique blend of expertise. It includes Dr. Micha Breakstone, a notable repeat AI entrepreneur, alongside the Head of the Fundamental AI Group at MIT, who pioneered foundational research in scaling laws. The team also comprises four Harvard Medical School professors and members of the National Academy of Sciences/Medicine, including the Chair of the Genetics Department at HMS, providing a strong scientific and entrepreneurial foundation.
This significant investment positions Somite AI to further solidify its leadership in applying advanced AI to stem cell research. The company plans to leverage this capital to drive innovation, overcome current bottlenecks in cell therapy development, and ultimately deliver new, scalable therapeutic solutions that promise to impact patient care profoundly.
.png&w=3840&q=75)
